Vobarilizumab
From WikiMD's WELLNESSPEDIA
| Vobarilizumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1628814-88-9 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | D11005 |
Vobarilizumab (ALX0061) (INN) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.[1][2]
This drug was developed by Ablynx NV.
References[edit]
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.
- ↑ World Health Organization."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114".WHO Drug Information.2015;29(4)Full text.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page. |
| This article is a stub. You can help WikiMD by registering to expand it. |
| This article is a stub. You can help WikiMD by registering to expand it. |
